SEC.gov | Becton Dickinson to Pay $175 Million for Misleading …

Dec 16, 2024 · The Securities and Exchange Commission today announced settled charges against Becton, Dickinson and Company, a New Jersey-based medical device manufacturer …

$175
OFF

SEC.gov | Becton Dickinson To Pay $175 Million For Misleading …

3 weeks from now

Dec 16, 2024 · The Securities and Exchange Commission today announced settled charges against Becton, Dickinson and Company, a New Jersey-based medical device manufacturer …

sec.gov

$175
OFF

BD Agrees To Pay $175 Mln To Settle With SEC Over Alaris System ...

3 weeks from now

Dec 17, 2024 · (RTTNews) - Becton, Dickinson and Co. (BDX) or BD, a New Jersey-based medical device manufacturer, has agreed to pay $175 million to the U.S. Securities and …

businessinsider.com

$175
OFF

BD Agrees To Pay $175 Mln To Settle With SEC Over Alaris System ...

3 weeks from now

Dec 17, 2024 · Becton, Dickinson and Co. or BD, a New Jersey-based medical device manufacturer, has agreed to pay $175 million to the U.S. Securities and Exchange …

rttnews.com

$175
OFF

BD Resolves Previously Disclosed SEC Investigation - Yahoo Finance

3 weeks from now

As part of the settlement, BD has agreed to pay $175 million to the SEC, an amount that was reserved and disclosed in the company's fiscal year 2024 Form 10-K and was contemplated in …

yahoo.com

$175
OFF

Becton Dickinson To Pay $175 Million For Misleading Investors

3 weeks from now

Dec 16, 2024 · BD agreed to pay a $175 million civil penalty. According to the SEC’s order, BD determined in 2016 that software changes made to the Alaris pump required regulatory …

nasdaq.com

$175
OFF

Becton Dickinson To Pay $175 Million For Misleading Investors On …

3 weeks from now

Dec 20, 2024 - Compliance & Ethics - Becton, Dickinson and Company (BD), a New Jersey-based medical device manufacturer, has agreed to pay a $175 million civil penalty to the …

grcreport.com

$175
OFF

Becton Dickinson Discloses Resolution With SEC Over Alaris System ...

3 weeks from now

Dec 16, 2024 · As part of the settlement, BD has agreed to pay $175 million to the SEC, an amount that was reserved and disclosed in the company’s fiscal year 2024 Form 10-K and …

businessinsider.com

$175
OFF

Becton Dickinson Settles Charges Over Infusion Pump Risks, SEC Says

3 weeks from now

Dec 16, 2024 · The SEC said Becton Dickinson agreed to pay a $175 million civil penalty to settle the charges, which also allege that the company overstated its income by failing to disclose …

yahoo.com

$175
OFF

BD To Pay $175M To Settle Charges Of Misleading Investors On …

3 weeks from now

Dec 17, 2024 · Dive Brief: BD will pay a $175 million civil penalty to settle charges from the Securities and Exchange Commission that the company misled investors about problems with …

medtechdive.com

$175
OFF

BD Pays $175M To Settle SEC Claims It Failed To Report Infusion …

3 weeks from now

Dec 17, 2024 · The Securities and Exchange Commission (SEC) today announced settled charges against Becton, Dickinson and Company (BD), a New Jersey-based medical device …

medicaldesigndevelopment.com

$175
OFF

BD To Pay SEC $175M To Settle Alaris Investigation

3 weeks from now

Dec 17, 2024 · Franklin Lakes, New Jersey–based BD agreed to pay $175 million to the SEC. This adds to an $85 million settlement to resolve a class action suit in New Jersey about a …

massdevice.com

$175
OFF

BD Resolves SEC Investigation With $175 Million Settlement …

3 weeks from now

Dec 18, 2024 · As part of the settlement, BD has agreed to pay $175 million to the SEC, an amount that was reserved and disclosed in the company's fiscal year 2024 Form 10-K and …

biopharmaboardroom.com

$175
OFF

BD Resolves SEC Investigation With $175 Million Settlement

3 weeks from now

Summary. Becton Dickinson & Co (BDX, Financial), a prominent global medical technology company, announced on December 16, 2024, that it has reached a settlement with the U.S. …

gurufocus.com

$175
OFF

Becton Dickinson To Pay $175 Million For Misleading Investors …

3 weeks from now

Dec 16, 2024 · The Securities and Exchange Commission today announced settled charges against Becton, Dickinson and Company, a New Jersey-based medical device manufacturer …

securitiesdocket.com

$175
OFF

Becton Dickinson To Pay $175 Million Fine Related To SEC …

3 weeks from now

Dec 16, 2024 · Becton Dickinson has agreed to pay a $175 million fine to settle an investigation by the U.S. Securities and Exchange Commission. The previously disclosed investigation was …

marketscreener.com

$175
OFF

BD Reaches $175M SEC Settlement Over Alaris System Disclosures ...

3 weeks from now

Dec 16, 2024 · BD (BDX) has reached a settlement with the SEC regarding an investigation into previous disclosures about the BD Alaris™ System, acquired from CareFusion in 2015.The …

stocktitan.net

$175
OFF

Becton Dickinson To Pay $175 Million To Settle SEC Investigation …

3 weeks from now

Dec 17, 2024 · The Securities and Exchange Commission announced settled charges against Becton, Dickinson and Company, a New Jersey-based medical device manufacturer known as …

jeffnewmanlaw.com

FAQs about SEC.gov | Becton Dickinson to Pay $175 Million for Misleading … Coupon?

Why did BD pay $175 million to the SEC?

(RTTNews) - Becton, Dickinson and Co. (BDX) or BD, a New Jersey-based medical device manufacturer, has agreed to pay $175 million to the U.S. Securities and Exchange Commission to resolve an investigation concerning past public disclosures and SEC reporting related to the BD Alaris System. ...

Why did the SEC settle charges against BD?

The Securities and Exchange Commission announced settled charges against BD for repeatedly misleading investors about risks associated with its continued sales of its Alaris infusion pump and for overstating its income by failing to record the costs of fixing multiple software flaws with the pump. ...

Did Becton Dickinson mislead investors about Alaris?

WASHINGTON (Reuters) - The U.S. Securities and Exchange Commission said on Monday that it had settled charges with Becton Dickinson and Co. (BD) over allegations it misled investors about risks associated with its Alaris infusion pump. ...

Why did BD sell the Alaris pump without regulatory clearance?

According to the SEC’s order, BD determined in 2016 that software changes made to the Alaris pump required regulatory clearance from the Food and Drug Administration (FDA). However, BD did not have the data required for clearance, and generating the data would delay the release of new features, so BD continued selling the pump without clearance. ...

Why did BD keep investors in the dark about Alaris?

“BD repeatedly painted a misleading picture of its Alaris infusion pump for investors and then doubled down by keeping them in the dark when the device’s issues came to a head with the FDA in late 2019,” said Sanjay Wadhwa, Acting Director of the SEC’s Division of Enforcement. ...

Why did BD stop selling Alaris?

The order finds that BD revealed Alaris’s software flaws to the FDA in October 2019 and proposed that the agency allow it to continue selling the pump while it worked to fix the flaws and complete the lengthy FDA clearance process. The FDA firmly rejected this proposal so BD immediately stopped shipping Alaris. ...